skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: I own shares in a small company, AFE if it is relevant, and today it is trading in what appears to be some form of automated fashion. Can you explain the logic and meaning, (if any), of this to me. I have seen it before with other issues as well.

Thanks

15:07:12 V 0.17 0.015 500 143 Pershing 53 Morgan Stanley
15:05:14 V 0.17 0.015 500 143 Pershing 53 Morgan Stanley
15:03:17 V 0.17 0.015 500 143 Pershing 53 Morgan Stanley
15:01:19 V 0.17 0.015 500 143 Pershing 53 Morgan Stanley
14:59:22 V 0.17 0.015 500 143 Pershing 53 Morgan Stanley
14:57:24 V 0.17 0.015 500 143 Pershing 53 Morgan Stanley
14:55:27 V 0.17 0.015 500 143 Pershing 53 Morgan Stanley
14:53:29 V 0.17 0.015 500 143 Pershing 53 Morgan Stanley
14:51:32 V 0.17 0.015 500 143 Pershing 53 Morgan Stanley
14:49:34 V 0.17 0.015 500 143 Pershing 53 Morgan Stanley
Read Answer Asked by Robert on March 26, 2018
Q: a followup to the results announced by Antibe, Knight (gud/t) has been given a spot of the Board of Directors. How significant is this news and what relationship does Knight have with Antibe,ie: have they previously participated in finance for shares,etc. I thought Knight would move on this news but in the red today. Thanks as usual, JB from beautiful Laurentian Mountains. PS:great spring skiing here
Read Answer Asked by John on March 21, 2018
Q: ATE is set to release final Phase 2b results of their lead drug ATB-346, in 4weeks. I'm curious if you have any relevant information on the outlook of this drug and the company overall? I understand GUD has funds deployed here. And my main question is if the trial results show less GI tract bleeding (the issue with prolonged doses of Naproxen) and better efficacy results than Aleve then how could the drug or company's valuation be estimated? Sales numbers for Bayer's Aleve that could be extrapolated? thanks
Read Answer Asked by Gordon on February 16, 2018
Q: Can you please comment or provide any opinion on ATE phase2 trials for their ATB-346 drug? my understanding is that results of liver tests in test patients have provided mixed results from the trials. Also please provide forecast for share price going forward based on potential drug trial success? I know they have been obtaining private funds and i believe GUD has 10 or 20% stake in ATE. thanks
Read Answer Asked by Gordon on February 13, 2017
Q: Hello team. I currently have a small position in Antibe Therapeutics and considering adding more. This is a stage 2 drug company. No profit and sales really that tie in to the real story of the drug being created at the moment. Essentially they are trying to create a pain medication that will compete with the likes of Advil/Tylenol without the negative side effects of damaging the stomach lining and creating ulcers. The most interesting component is that amount of activity of old Paladin Labs/ new Knight Therapeutics people moving in and out of the company, setting up acquisitions and financing deals. Considering you guys cover Knight I was wondering if you had any further analysis or information on Antibe or the financing deals that Knight puts together? Or perhaps you could criticize or add to my qualitative analysis for other areas I should be concerned about?

Pros:
From what I can tell it's the only other company that Johnathan Goodman holds a position in besides Knight.
In the 50% region of insider ownership.
The fact they acquired a sales force shows confidence.

Cons:
One patient got something similar to Jondis, this forced the company back to the drawing board. If the product is not considered safer than Advil, it will have a hard time selling.
Further dilution will have to occur to proceed in product testing.
Read Answer Asked by Liam on July 25, 2016
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!